iRGD as a tumor-penetrating peptide for cancer therapyHong Yin, Junnian Zheng, Jǐnjīng Xǔ et al.|Molecular Medicine Reports|2017Cited by 74
Bortezomib improves adoptive carbonic anhydrase�IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinomaQing Zhang, Junnian Zheng, Huizhong Li et al.|Oncology Reports|2018Cited by 29
Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG miceQing Zhang, Junnian Zheng, Haiyu Wang et al.|Oncotarget|2016Cited by 24
Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimensJǐnjīng Xǔ, Junnian Zheng, Kang Tian et al.|Expert Review of Anticancer Therapy|2017Cited by 22
Current status and future prospects of the strategy of combining CAR‑T with PD‑1 blockade for antitumor therapy (Review)Jǐnjīng Xǔ, Junnian Zheng, Haiyu Wang et al.|Molecular Medicine Reports|2017Cited by 18